CRDF logo

CRDF
Cardiff Oncology Inc

18,779
Mkt Cap
$108.02M
Volume
201.00
52W High
$4.56
52W Low
$1.48
PE Ratio
-2.27
CRDF Fundamentals
Price
$1.56
Prev Close
$1.58
Open
$1.58
50D MA
$1.76
Beta
1.48
Avg. Volume
599,040.97
EPS (Annual)
-$0.6864
P/B
2.35
Rev/Employee
$19,129.03
$130.35
Loading...
Loading...
News
all
press releases
Noble Financial Issues Optimistic Estimate for CRDF Earnings
Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - Research analysts at Noble Financial raised their Q1 2026 earnings per share (EPS) estimates for shares of Cardiff Oncology in a note issued to...
MarketBeat·9d ago
News Placeholder
More News
News Placeholder
Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seven ratings firms that are currently covering the stock, MarketBeat...
MarketBeat·12d ago
News Placeholder
Cardiff Oncology Showcases Onvansertib: 72% ORR Signal in Phase II RAS-Mutant mCRC Webinar
Cardiff Oncology (NASDAQ:CRDF) interim CEO Mani Mohindru outlined updated clinical results and development plans for the company's investigational PLK1 inhibitor onvansertib during a webinar focused...
MarketBeat·13d ago
News Placeholder
What is Zacks Research's Forecast for CRDF FY2027 Earnings?
Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - Investment analysts at Zacks Research lowered their FY2027 EPS estimates for Cardiff Oncology in a note issued to investors on Monday, March 2nd...
MarketBeat·1mo ago
News Placeholder
Cardiff Oncology (NASDAQ:CRDF) Upgraded at Wall Street Zen
Wall Street Zen upgraded shares of Cardiff Oncology from a "sell" rating to a "hold" rating in a research note on Wednesday...
MarketBeat·1mo ago
News Placeholder
Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Consensus Recommendation of "Moderate Buy" by Analysts
Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) has earned an average rating of "Moderate Buy" from the seven analysts that are covering the company, MarketBeat reports. One research analyst...
MarketBeat·1mo ago
News Placeholder
HC Wainwright Issues Optimistic Outlook for CRDF Earnings
Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - Equities research analysts at HC Wainwright increased their Q1 2026 EPS estimates for Cardiff Oncology in a note issued to investors on Wednesday...
MarketBeat·1mo ago
News Placeholder
Cardiff Oncology Spotlights Onvansertib Data at Oppenheimer: 72% ORR in RAS-Mutant mCRC
Cardiff Oncology (NASDAQ:CRDF) used an appearance at Oppenheimer's 36th Annual Healthcare Conference to highlight updated clinical results and its development plans for onvansertib, an oral, highly...
MarketBeat·1mo ago
News Placeholder
Piper Sandler Has Lowered Expectations for Cardiff Oncology (NASDAQ:CRDF) Stock Price
Piper Sandler reduced their price objective on shares of Cardiff Oncology from $10.00 to $6.00 and set an "overweight" rating for the company in a research note on Wednesday...
MarketBeat·1mo ago
News Placeholder
Cardiff Oncology (NASDAQ:CRDF) Announces Quarterly Earnings Results
Cardiff Oncology (NASDAQ:CRDF - Get Free Report) released its earnings results on Tuesday. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.18...
MarketBeat·1mo ago
<
1
2
...
>

Latest CRDF News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.